<DOC>
	<DOCNO>NCT00803283</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety Osmotic Release Oral System ( OROS ) hydromorohone Hydrochloride ( HCl ) compare morphine sustain release ( SR ) participant chronic ( last long time ) malignant ( cancerous ) cancer pain .</brief_summary>
	<brief_title>A Study Compare Safety Efficacy Osmotic Release Oral Syytem ( OROS ) Hydromorphone Hydrochloride ( HCl ) With Morphine Sustain Release ( SR ) Participants With Cancer Pain</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( 1 hospital medical school team work medical research study ) , active-controlled , randomize ( study drug assign chance ) study evaluate safety efficacy OROS extended-release ( ER ) hydromorhone HCl compare twice daily morphine SR , Taiwan participants cancer pain . The study consist 3 phase : Screening phase ( 14 day administration study drug ) , Dose titration phase ( 3 14 day ) Dose maintenance phase ( 14 day ) . This study include 8 visit ( Visit 1 [ Day 1 ] , Visit 2 [ Day 1-13 telephonic ] , Visit 3 [ Day 14 ] , Visit 4 [ Day 15 Day 21 telephonic ] , Visit 5 [ Day 22 ] , Visit 6 [ Day 23 27 telephonic ] Visit 7 [ Day 28 ] ) . In dose titration phase , participant randomly assign 1 2 treatment , OROS hydromorphone morphine SR dose study medication adjust every 48 hour Investigator 's discretion accord participant 's analgesic ( drug use control pain ) requirement . Morphine HCl use rescue medication ( maintain 3 dos per day le ) breakthrough pain . Participants primarily evaluate equivalence efficacy use `` bad pain '' item brief pain inventory ( BPI ) . Participants ' safety monitor throughout study duration .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<mesh_term>Sulfamethazine</mesh_term>
	<criteria>Participants cancer pain experience inadequate pain control approach Step 2 World Health Organisation ( WHO ) analgesic ladder Participants pain score great equal 4 average last 24 hour Participants require expect require 540 milligram oral morphine morphine equivalent every 24 hour management chronic cancer pain Participants reasonably expect achieve stable dose opioid study medication duration trial Participants reasonably expect achieve stable dose opioid study medication duration trial Participants pure predominantly neuropathic pain pain unknown origin ( mechanism physical cause identify ) Participants acute pain pain movement Participants receive fentanyl patch within last 5 day Participants intolerant hypersensitive hydromorphone opioids agonist ( chemical substance capable activate receptor induce full partial response ) Participants recent past history ( within previous 5 year ) current history drug abuse alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Pain</keyword>
	<keyword>Hydromorphone hydrochloride OROS</keyword>
	<keyword>Morphine</keyword>
</DOC>